Source
Trials. 5/12/2016, Vol. 17, p1-12. 12p. 1 Diagram, 3 Charts.
Subject
*PACLITAXEL
*ARTERIOVENOUS fistula
*HEMODIALYSIS
*ANGIOPLASTY
*ANTINEOPLASTIC agents
*SURGICAL arteriovenous shunts
*BIOMEDICAL materials
*BLOOD vessels
*CARDIOVASCULAR agents
*COMPARATIVE studies
*EXPERIMENTAL design
*VASCULAR resistance
*RESEARCH methodology
*MEDICAL cooperation
*MEDICAL equipment
*RESEARCH protocols
*RESEARCH
*RESEARCH funding
*STATISTICAL sampling
*SURGICAL complications
*TIME
*TRANSLUMINAL angioplasty
*VASCULAR grafts
*EVALUATION research
*RANDOMIZED controlled trials
*TREATMENT effectiveness
*BLIND experiment
*EQUIPMENT & supplies
TREATMENT of surgical complications
Abstract
Background: The initial therapy for a stenosis in an arteriovenous fistula used for haemodialysis is radiological balloon dilatation or angioplasty. The benefit of angioplasty is often short-lived, intervention-free survival is reported to be 40-50 % at 1 year. Previous small studies and observational data suggest that paclitaxel-coated balloons may be of benefit in improving outcomes after fistuloplasty of stenotic arteriovenous fistulae.Methods/design: We have designed a multicentre, double-blind randomised controlled trial to test the superiority of paclitaxel-coated balloons for preventing restenosis after fistuloplasty in patients with a native arteriovenous fistula. Two hundred and eleven patients will be followed up for a minimum of 1 year. Inclusion criteria include a clinical indication for a fistuloplasty, an access circuit that is free of synthetic graft material or stents, and a residual stenosis of 30 % or less after plain balloon fistuloplasty. Exclusion criteria include a synchronous venous lesion in the same access circuit, location of the stenosis central to the thoracic inlet or a thrombosed access circuit at the time of treatment. The primary endpoint is time to end of target lesion primary patency. This is defined as a clinically-driven radiological or surgical re-intervention at the treatment segment, thrombosis that includes the treatment segment, or abandonment of the access circuit due to an inability to re-treat the treatment segment. Secondary endpoints include angiographic late lumen loss, time to end of access circuit cumulative patency, the total number of interventions, and quality of life. The trial is funded by the National Institute for Health Research.Discussion: We anticipate that this trial will provide rigorous data that will determine the efficacy of additional paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis.Trial Registration: ISRCTN14284759 . Registered on 28 October 2015. [ABSTRACT FROM AUTHOR]